Literature DB >> 17611683

Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.

Hiroaki Kajiyama1, Kiyosumi Shibata, Mikio Terauchi, Mamoru Yamashita, Kazuhiko Ino, Akihiro Nawa, Fumitaka Kikkawa.   

Abstract

The aim of this study was to assess paclitaxel resistant-epithelial ovarian carcinoma (EOC) cells for cellular morphology, motility, and molecular changes consistent with epithelial-mesenchymal transition (EMT). The human EOC cell lines NOS-2, TAOV and SKOV-3 were continuously exposed to increasing doses of paclitaxel to establish three stable cell lines resistant to paclitaxel (NOS-PR, TAOV-PR, and SKOV-PR cells, respectively). Using these cell lines, cellular functions such as motility, invasive ability, and proliferative potential were assessed. Several molecules involved in EMT or cell invasiveness were assessed using Western blot analysis. In a peritoneal metastasis model using mice inoculated with NOS-2 or NOS-PR cells, we investigated the differences of peritoneal dissemination and survival time. NOS2-PR cells showed phenotypic changes consistent with EMT; with spindle-shaped morphology and enhanced pseudopodia formation. Western blot analysis revealed decreased expression of the epithelial adhesion molecule, E-cadherin and an increase in mesenchymal markers such as vimentin, fibronectin and smooth-muscle actin in NOS-PR cells compared to NOS-2 cells. The NOS2-PR cells displayed increased expression of Snail and Twist, EMT-regulatory transcription factors. Migratory potential in a wound assay and metastatic potential to the peritoneum of mice were markedly enhanced in NOS2-PR cells compared to NOS-2 cells. These data suggest that there is a possible link between chronic paclitaxel-resistance and induction of the EMT in EOC cells. It is possible that therapeutic benefits such as the restoration of chemosensitivity or suppression of metastasis will be enabled by gaining further insight into the mechanisms underlying chemoresistance and EMT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611683

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  184 in total

1.  Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis.

Authors:  A Bagnato; L Rosanò
Journal:  Curr Oncol       Date:  2012-02       Impact factor: 3.677

2.  Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Authors:  Hans J Hammers; Henk M Verheul; Brenda Salumbides; Rajni Sharma; Michelle Rudek; Janneke Jaspers; Preeti Shah; Leigh Ellis; Li Shen; Silvia Paesante; Karl Dykema; Kyle Furge; Bin T Teh; George Netto; Roberto Pili
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

3.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

4.  Twist1 is a potential prognostic marker for colorectal cancer and associated with chemoresistance.

Authors:  Da-Jian Zhu; Xiao-Wu Chen; Wei-Jie Zhang; Jia-Zhi Wang; Man-Zhao Ouyang; Qiang Zhong; Chang-Chun Liu
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

5.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.

Authors:  Geoffrey Kim; Ben Davidson; Ryan Henning; Junbai Wang; Minshu Yu; Christina Annunziata; Thea Hetland; Elise C Kohn
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 6.  MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer.

Authors:  Zhipin Liang; Yaguang Xi
Journal:  Chin J Nat Med       Date:  2016-12

7.  Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Authors:  Andressa Ardiani; Sofia R Gameiro; Claudia Palena; Duane H Hamilton; Anna Kwilas; Thomas H King; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

8.  Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Authors:  Francois Moisan; Edgar B Francisco; Anamaria Brozovic; George E Duran; Yan C Wang; Shalini Chaturvedi; Shobha Seetharam; Linda A Snyder; Parul Doshi; Branimir I Sikic
Journal:  Mol Oncol       Date:  2014-04-18       Impact factor: 6.603

Review 9.  Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition.

Authors:  Jeffrey T Chang; Sendurai A Mani
Journal:  Cancer Lett       Date:  2013-03-14       Impact factor: 8.679

10.  Alteration in TWIST expression: possible role in paclitaxel-induced apoptosis in human laryngeal carcinoma Hep-2 cell line.

Authors:  Liang Yu; Hui-Zheng Li; Su-Mei Lu; Wen-Wen Liu; Jian-Feng Li; Hai-Bo Wang; Wei Xu
Journal:  Croat Med J       Date:  2009-12       Impact factor: 1.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.